ArticleScientific reports2015
Automated astatination of biomolecules--a stepping stone towards multicenter clinical trials.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Astatine-211-Towards In Vivo Stable Astatine-211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications.Medicinal research reviews · 2026Review
- Astatine-211 radiolabelling chemistry: from basics to advanced biological applications.EJNMMI radiopharmacy and chemistry · 2024Review
- A proposed production method for astatinated (At-211) Trastuzumab for use in a Phase I clinical trial.PloS one · 2024Article
- Astatine-211 based radionuclide therapy: Current clinical trial landscape.Frontiers in medicine · 2022Review
- Production and Supply of α-Particle-Emitting Radionuclides for Targeted α-Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Review
- Synthesis of [Scientific reports · 2021Article
- Evaluation of therapeutic efficacy ofTranslational oncology · 2021Article
- Labeling Monoclonal Antibody with α-emittingCancer biotherapy & radiopharmaceuticals · 2020Article
- Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure.Cancer biotherapy & radiopharmaceuticals · 2020Review
- Development of an autonomous solvent extraction system to isolate astatine-211 from dissolved cyclotron bombarded bismuth targets.Scientific reports · 2019Article
- Towards elucidating the radiochemistry of astatine - Behavior in chloroform.Scientific reports · 2019Article
- Multifunctional Clickable Reagents for Rapid Bioorthogonal Astatination and Radio-Crosslinking.ChemPlusChem · 2019Article
- Rapid Cu-Catalyzed [Organic letters · 2018Article
- Targeted radionuclide therapy with astatine-211: Oxidative dehalogenation of astatobenzoate conjugates.Scientific reports · 2017Article
- Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.Expert opinion on biological therapy · 2016Review
- Improved production ofNuclear medicine and biologyArticle
- Production, purification and availability ofNuclear medicine and biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To facilitate multicentre clinical studies on targeted alpha therapy, it is necessary to develop an automated, on-site procedure for conjugating rare, short-lived, alpha-emitting radionuclides to biomolecules. Astatine-211 is one of the few alpha-emitting nuclides with appropriate chemical and physical properties for use in targeted therapies for cancer. Due to the very short range of the emitted α-particles, this therapy is particularly suited to treating occult, disseminated cancers. Astatine is not intrinsically tumour-specific; therefore, it requires an appropriate tumour-specific targeting vector, which can guide the radiation to the cancer cells. Consequently, an appropriate method is required for coupling the nuclide to the vector. To increase the availability of astatine-211 radiopharmaceuticals for targeted alpha therapy, their production should be automated. Here, we present a method that combines dry distillation of astatine-211 and a synthesis module for producing radiopharmaceuticals into a process platform. This platform will standardize production of astatinated radiopharmaceuticals, and hence, it will facilitate large clinical studies focused on this promising, but chemically challenging, alpha-emitting radionuclide. In this work, we describe the process platform, and we demonstrate the production of both astaine-211, for preclinical use, and astatine-211 labelled antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.